PRQR Stock Recent News

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES Europe, that is being held November 16-18, 2022 in Vienna, Austria.

ProQR (PRQR) delivered earnings and revenue surprises of -47.83% and 7.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th Annual Retinal Cell and Gene Therapy Innovation Summit being held Friday, April 29, 2022 and the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) being held May 1-4, 2022, both in Denver, CO, U.S.

ProQR Therapeutics N.V. (NASDAQ: PRQR) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform.

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a presentation at the 3rd RNA Editing Summit held April 5-7 in Boston, MA, US.